RARE | Page 1 | RegMed Investors

utility

header_second

RegMed Investors (RMi) went exclusive on July 27th!

Your complimentary subscription to RegMed Investors’ (RMi) reporting on the stem, cell and gene therapy and RegMed sector has expired.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

It’s up to you to choose the level of content access to provide a premium experience and value - don’t wait to exhale!

I also bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of trading, investment or I-Banking.

So, after these years of following our facts … first and fast; be part of our “inner circle” as a subscriber!

Stay with me and join our coalition and have a seat at the appreciation table!

Login Sign up now Not now

content_top

34 companies, 1 interpreter! Insight, foresight
and recommendation

22.44

1.02

(102.00%)

content_middle

Previous Close:

21.42

52wk Range:

18.29 - 42.37

Market Capitalization:

0.00M

Shares Outstanding:

0.00M

content_right

March 8, 2026 - 4:10pm | Out and About, Research Notes, Out and About, Financings
RMI Financing Note: Solid Biosciences (SLDB) $240 M Private Placement

SLDB
February 15, 2026 - 4:37pm | Out and About, Research Notes, Out and About, Earnings
RegMed Investors (RMi) Q4/25 and FY25 Cell and Gene Therapy Earnings

ALNY, ARWR, MRNA, IQV, RARE, VRTX, CRSP
October 12, 2025 - 5:34pm | Out and About, Research Notes, Out and About
RMi Research Note: Japan’s Takeda (TAK) exits cell and gene therapy (CGT) research with $395 M write-off

TAK
December 3, 2024 - 4:32pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q3
RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results

SAGE, MDXG
November 7, 2024 - 8:51am | Out and About, Research Notes, Out and About, Earnings Alert, Earnings
RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates

ALNY, IONS, VCEL, AGEN, AXGN, RARE, BLFS, RGNX, CRSP, LENZ, CRBU, VCEL, VERV, EDIT, AGEN, IONS, QURE, BEAM, SAGE, MDXG, ALNY, BPMC, AXGN, RARE
June 14, 2024 - 8:45am | Out and About, Research Notes, Out and About, Financings
RegMed Investors (RMi) Research/Financing Note: Ultragenyx Pharmaceutical (RARE) priced offering of 7,435,898 shares at $39.00 per share.

RARE
February 20, 2024 - 11:49am | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q3
RegMed Investors (RMi) Research Note: Q4/23 earnings reporting dates, net losses, cash positions and runway outcomes

MDXG, GBIO, AXGN, VCEL, BLFS, QURE, EDIT, VERV, MDXG, VYGR, MESO, RGNX, BEAM, VERV, FATE, NTLA, CRSP, IONS, SAGE, RARE, BPMC, ALNY
January 18, 2024 - 8:57pm | Out and About, Research Notes, Out and About
RegMed Investors (RMi) Research Note: Mesoblast (MESO) FDA Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L)

MESO
January 2, 2024 - 10:45am | Out and About, Research Notes, Out and About
RegMed Investors (RMi) Research Note: Voyager Therapeutics (VYGR) juices after Novartis (NVS) licensing deal

NVS, VYGR
October 18, 2023 - 11:38pm | Out and About, Research Notes, Out and About, Financings
RegMed Investors (RMi) Research Note: Ultragenyx Pharmaceutical (RARE) has priced its public offering at $30.00 per share of 8,33 M stock

RARE
August 18, 2023 - 4:09pm | Out and About, Research Notes, Out and About, Earnings Alert, Earnings
RegMed Investors (RMi) Research Note: Q2/23 net losses earnings, cash positions and runway outcomes

QURE
July 31, 2023 - 7:19am | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q2
RegMed Investors (RMi) Research Note: Q2/2023 earnings reporting date announcements

MDXG, BPMC, VCEL, ALNY, EDIT, NTLA, BEAM, VERV, PRME, CRSP
June 12, 2023 - 11:16am | Out and About, Research Notes, Out and About
RegMed Investors (RMi) Research Note: Intellia Therapeutics (NTLA +$2.30 or +5.32% TO $45.54) pops on news of its CRISPR-based gene-editing drug almost completely eliminated attacks in a rare swelling disease

NTLA
May 27, 2023 - 12:37pm | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q1
RegMed Investors (RMi) Research Note: Q1/23 earnings reporting dates, net losses, cash positions and runway outcomes

SGMO, SAGE, MDXG, AXGN
May 15, 2023 - 11:40am | Out and About, Research Notes, Out and About
UniQure NV (QURE) to sell royalty interest in blood disorder therapy for up to $400 M

QURE
April 10, 2023 - 4:40pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting

SAGE, RARE, CRSP, EDIT, VCEL, NTLA, QURE, MESO, BEAM, VYGR, KDNY, FIXX, CRBU, AGEN, AXGN, VSTM, BLUE, ADVM, BCLI
January 25, 2023 - 10:55am | Out and About, Research Notes, Out and About, Financings
Precigen (PGEN) $75 M offering priced at $1.75

PGEN
September 30, 2022 - 8:27am | Out and About, Research Notes, Out and About
Solid Biosciences (SLDB) announces acquisition of Aavanti Bio Inc (private)and concurrent $75 Million Private Placement

SLDB
September 21, 2022 - 8:47pm | Out and About, Research Notes, Out and About
bluebird bio (BLUE) announced the FDA has granted Accelerated Approval of SKYSONA® (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrop

bluebird bio (BLUE)
August 16, 2022 - 11:38am | Out and About, Research Notes, Out and About
RegMed Investors’ (RMI) Earnings: dates of releases and more results

RARE, ALNY, SAGE, AXGN, VCEL, MDXG, EDIT, FATE, NTLA, AGEN, IONS

Pages

footer

© 2015 RegMed Investors (regmedinvestors.com), all rights are reserved.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry MCusker . Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of RegMed Investors (RM-i); who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other RM-i media services or reposting please email hwm@regmedinvestors.com.